C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) C07D 519/00 (2006.01) A61P 11/00 (2006.01) A61P 17/00 (2006.01) A61P 19/00 (2006.01) A61P 25/00 (2006.01) A61P 31/00 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01)
Patent
CA 2735956
The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed herein can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4 /PDE type 7 inhibitors are provided.
La présente invention concerne des inhibiteurs de la phosphodiestérase (PDE) de type 4, de la phosphodiestérase (PDE) de type 7, et un double inhibiteur de PDE de type 4 / PDE de type 7. Les composés de l'invention conviennent au traitement, à la prévention, à l'inhibition ou à la suppression de maladies du système nerveux central telles que la sclérose en plaques; de divers états pathologiques affectant le système immunitaire et notamment le SIDA, le rejet de greffe, les maladies auto-immunes telles que les maladies relatives aux lymphocytes T comme par exemple la polyarthrite rhumatoïde; de maladies inflammatoires telles que les maladies inflammatoires respiratoires et notamment la broncho-pneumopathie chronique obstructive, l'asthme, la bronchite, la rhinite allergique, le syndrome de détresse respiratoire aigüe, et autres maladies inflammatoire dont notamment, sans que la liste ne soit limitative, le psoriasis, le choc, la dermite atopique, le granulome à éosinophiles, la conjonctivite allergique, et l'arthrose; de maladies inflammatoires gastro-intestinales telles que la maladie de Crohn, la colite, la pancréatite, ainsi que différents types de cancers dont la leucémie; et en particulier chez les humains. L'invention concerne également des procédés d'élaboration des composés de l'invention, des compositions pharmaceutiques contenant les composés de l'invention, et leur utilisation comme inhibiteurs de la phosphodiestérase (PDE) de type 4, de la phosphodiestérase (PDE) de type 7, et comme double inhibiteur de PDE de type 4 / PDE de type 7.
Chandrakant Kakade Ganesh
Dastidar Sunanda G.
Gupta Nidhi
Jain Tarun
Ray Abhijit
Dimock Stratton Llp
Ranbaxy Laboratories Limited
LandOfFree
Phosphodiestarase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiestarase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiestarase inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1988487